Logo

• Under development gynecological cancer (KGOG3015)

  A multicenter study to develop a peritoneal carcinomatosis index (PCI) in patients with epithelial ovarian cancer, tubal cancer and primary peritoneal cancer to estimate perioperative tumor burden objectively

  • PI / PI기관 Sang-Yoon Park /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 0 person / 134 person (0.0%)

• Under development gynecological cancer (KGOG3003S1)

  The safety of fertility sparing management in stage 1 ovarian clear cell carcinoma

  • PI / PI기관 Jeong Yeol Park /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 0 person / 0 person (0.0%)

• Under development gynecological cancer (KGOG2029)

  Prospective randomized comparison of Sentinel Lymph Node Mapping Using Indocyanine Green and conventional pelvic lymph node dissection in Clinical Stage I II Endometrial Cancer

  • PI / PI기관 Jeong Yeol Park /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 0 person / 810 person (0.0%)

• Under development gynecological cancer (KGOG2027)

  NRG-GY020: A PHASE III RANDOMIZED TRIAL OF RADIATION +/- MK-3475 (PEMBROLIZUMAB) FOR NEWLY DIAGNOSED EARLY STAGE HIGH INTERMEDIATE RISK MISMATCH REPAIR DEFICIENT (dMMR) ENDOMETRIOID ENDOMETRIAL CANCER

  • PI / PI기관 Jeong Yeol Park /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 32 person / 168 person (19.0%)

• Under development gynecological cancer (KGOG2025)

  AtTEnd: Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer

  • PI / PI기관 Chul Min Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 550 person / 550 person (100.0%)

• Under development gynecological cancer (KGOG2023)

  Efficacy of adjuvant hormone therapy in patients with low or low-intermediate risk endometrial cancer combined by positive peritoneal cytology: a multicenter trial

  • PI / PI기관 Banghyun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 0 person / 66 person (0.0%)

• Under development gynecological cancer (KGOG2022)

  NRG-GY018: A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER

  • PI / PI기관 Beob-Jong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 461 person / 810 person (56.89999999999999%)

• Under development gynecological cancer (KGOG1046)

  AFTER trial: Adjuvant Chemotherapy Versus Radiotherapy For Postoperative Cervical Cancer ; a phase 3 trial

  • PI / PI기관 Seung-Hyuk Shim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 0 person / 50 person (0.0%)

• Under development gynecological cancer (KGOG1044)

  Feasibility of HPV DNA and vaginal infectious disease detection in mail-delivered self obtained vaginal sample obtained by G+Kitⓡ (SELPAX-I)

  • PI / PI기관 Moon-Hong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 0 person / 316 person (0.0%)

• Under development gynecological cancer (KGOG1039)

  Impact of Metformin on Survival Outcome in Recurrent, Metastatic, and Persistent Cervical Cancer with Paclitaxel, Cisplatin, and Bevacizumab: Open Label Prospective Multicenter Randomized Control Trial

  • PI / PI기관 Min-Hyun Baek /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 0 person / 0 person (0.0%)

* (사)대한부인종양연구회는 게시된 세부 임상연구 정보에 대해 법적 책임이 없습니다.